Solid Biosciences Inc. (SLDB)
Chart Events
Performance Outlook
| Previous Close | 0.5374 |
| Open | 0.5462 |
| Bid | 0.5050 x 1200 |
| Ask | 0.5900 x 800 |
| Day's Range | 0.5002 - 0.5893 |
| 52 Week Range | 0.4200 - 4.9150 |
| Volume | |
| Avg. Volume | 805,506 |
| Market Cap | 60.211M |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Solid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient advocacy conferences: American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting – May 16-19, 2022, Washington, D.C.Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will pr
- GlobeNewswire
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid development to continue, supported by new preclinical data; Company anticipates early-2023 Investigational New Drug (IND) submission for SGT-003 for Duchenne - - Strategy and resource alignment support funding of operations through important clinical milestones and into Q2 2024 - - Solid Biosciences
- GlobeNewswire
Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. Management will host a conference call on the same date beginning at 8:00 a.m. ET to discuss the Company’s financial results and a strategic update to develop SGT-001 and
